<DOC>
	<DOCNO>NCT01049243</DOCNO>
	<brief_summary>The purpose research study well understand fluocinonide cream 0.1 % ( Vanos® ) work people use treat atopic dermatitis day .</brief_summary>
	<brief_title>A Study Evaluating Efficacy Fluocinonide Cream 0.1 % ( Vanos ) Subjects With Atopic Dermatitis</brief_title>
	<detailed_description>This single center study . This open label study fluocinonide cream 0.1 % ( Vanos™ ) subject mild severe atopic dermatitis assessment 2 4 Investigator Global Assessment scale ( Appendix B ) . Up 20 subject age 12 enrol providing informed consent . All subject receive study medication , fluocinonide cream 0.1 % ( Vanos™ ) . Each subject instruct use fluocinonide cream 0.1 % ( Vanos™ ) twice daily three consecutive day ( total 6 dos ) . The study period last approximately 2 week . Subjects evaluated baseline Day 2 3 ( need achieve 6 dos ) , day 7 day 14 ( end study ) . Subjects apply study drug 6 dos .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Fluocinonide</mesh_term>
	<criteria>Male female mild severe atopic dermatitis , 12 year age old , agree participate provide write consent ( assent applicable ) Have Investigator Global Assessment mild severe atopic dermatitis ( IGA rating 2 4 Investigator Global Assessment ( Appendix B ) ) Percentage overall body surface involvement ( BSA ) must ≥2 % Women child bear potential allow participate study , subject require use least one form birth control Use within 4 week baseline systemic anti‐inflammatory medication , may influence study outcome , systemic corticosteroid Application use within 2 week baseline topical corticosteroid medication topical anti‐inflammatory medication , may influence study outcome Presence concurrent medical condition , determine investigator potentially interfere study outcome patient assessment Introduction prescription medication , topical systemic , atopic dermatitis participate study Amount disease involvement would require &gt; 60 gm cream 1 week period Subjects know allergy sensitivity topical Vanos™ cream component Pregnant woman woman breastfeed exclude . Women childbearing potential allow participate study , subject require use least one form birth control .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Open-Label</keyword>
	<keyword>Topical</keyword>
	<keyword>Cream</keyword>
	<keyword>Eczema</keyword>
	<keyword>Vanos</keyword>
</DOC>